Where does it say that the treatment group resulted in reduced vision? It doesn't, in fact their BVCA score improved.
AVA-101 Ph1 study.... the control group lost 3.5 letters, so even if you use that as the basis the Ph2 results are still significant at +5.7 letters for AVA-101 vs control.
I agree w/ trevor. The CEO stated in the conf call that retinal thickness change was pretty much the same for both 101 and control groups between week 8 and 52.
Not true. A lot of risk has been removed along with the high cost of development. as well as the marketing risk. JNJ isn' t just a passive investor, they bring a lot of expertise to the table.
The risk/reward profile of ACHN has improved significantly. Yes there is less potential upside, but the burn rate and overall risk is also much less.
They don't stop trials but will recommend that they do in case of futility. There is an ethical component to this also, when a drug clearly does not work and the trial continues.